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Abstract
Background: The rate of caesarean sections around the world is rising each year, reaching epidemic proportions.
Although many caesarean sections are performed for concerns about fetal welfare on the basis of abnormal
cardiotocography, the majority of babies are shown to be well at birth, meaning that the operation, with its
inherent short and long term risks, could have been avoided without compromising the baby’s health. Previously,
fetal scalp blood sampling for pH estimation was performed in the context of an abnormal cardiotocograph, to
improve the identification of babies in need of expedited delivery. This test has largely been replaced by lactate
measurement, although its validity is yet to be established through a randomised controlled trial. This study aims
to test the hypothesis that the performance of fetal scalp blood lactate measurement for women in labour with
an abnormal cardiotocograph will reduce the rate of birth by caesarean section from 38 % to 25 % (a 35 %
relative reduction).
Methods/Design: Prospective unblinded randomised controlled trial conducted at a single tertiary perinatal centre.
Women labouring with a singleton fetus in cephalic presentation at 37 or more weeks’ gestation with ruptured
membranes and with an abnormal cardiotocograph will be eligible. Participants will be randomised to one of
two groups: fetal monitoring by cardiotocography alone, or cardiotocography augmented by fetal scalp blood
lactate analysis. Decisions regarding the timing and mode of delivery will be made by the treating team, in accordance
with hospital protocols.
The primary study endpoint is caesarean section with secondary outcomes collected from maternal, fetal and neonatal
clinical course and morbidities. A cost effectiveness analysis will also be performed. A sample size of 600 will provide
90 % power to detect the hypothesised difference in the proportion of women who give birth by caesarean section.
Discussion: This world-first trial is adequately powered to determine the impact of fetal scalp blood lactate
measurement on rates of caesarean section. Preventing unnecessary caesarean sections will reduce the health
and financial burdens associated with this operation, both in the index and any future pregnancies.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12611000172909
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Background
There is currently an epidemic of caesarean sections
performed in Australia and overseas [1]. Although many
caesarean sections are performed for concerns about
fetal welfare, the majority of babies are shown to be well
at birth, meaning that the operation, with its inherent
short- and long-term risks, could possibly have been
avoided, without compromising the baby’s health. This
project is a randomised trial of fetal scalp blood sam-
pling for lactate measurement during labour, with a view
to reducing the caesarean section rate for apparently
non-reassuring fetal status. The trial proposal derives
from the Cochrane systematic review of intrapartum
fetal scalp blood sampling for lactate measurement [2],
which highlighted the need for a randomised trial of its
effectiveness.
It is imperative that a randomised controlled trial of
lactate measurement be conducted so that potentially
unnecessary caesarean sections can be avoided, that may
otherwise harm, rather than help, mothers and their
babies. As such, this will be a world-first trial.
The burden of disease associated with caesarean sections
Despite the evidence that caesarean section rates above
15 % seem to do more harm than good [3], countries
such as Australia, the United States of America and
China report alarmingly high rates of 27-50 % [1, 4, 5].
The Australian caesarean section rate of 32 % translates
to over 95,000 women having this surgery per year, with
over 39,000 of these occurring following the onset of
labour [4].
Risks that are increased with a caesarean birth include
anaesthetic risks, maternal infection, venous thrombo-
embolism, haemorrhage [6, 7] and intensive care unit
admissions for babies with breathing difficulties [8].
Having had a caesarean section delivery increases risks
in subsequent pregnancies of having further caesarean
sections, stillbirth, rupture of the uterus, hysterectomy
and increased bleeding due to the placenta implanting
over the scar [9–11]. These concerns must be balanced
against the need on occasions to urgently deliver a sick
baby who would be compromised by remaining in the
uterus.
A common indication for caesarean sections following
the onset of labour is the identification of a non-
reassuring fetal heart rate pattern. The chief investigator
of this study has previously found that 38 % of Austra-
lian labouring women, where a non-reassuring fetal
heart rate pattern had been identified, proceeded to de-
livery by caesarean section if no further testing of fetal
well-being was performed (i.e. for pH or lactate). On the
other hand, the caesarean section rate was 10 % when
such testing was undertaken [12].
Cardiotocography assessment of fetal well-being during
labour
Cardiotocography (CTG), which detects and records the
fetal heart rate by Doppler along with uterine contrac-
tions, was introduced into clinical practice in the 1960s
with the aim of improving perinatal outcomes by im-
proving intrapartum fetal welfare surveillance. A recent
clinical audit revealed that 71 % of labouring women
have continuous CTG in labour at the Royal Women’s
Hospital, Melbourne. Fetal heart rate patterns can be
classified in a number of ways. These include: (i) nor-
mal/reassuring; and (ii) when non-reassuring, a range of
terms including non-reassuring, suspicious, atypical, ab-
normal, pathological or ominous. These classifications
are based on the fetal heart rate, its variability and the
presence of accelerations or decelerations, compared
with the occurrence of uterine contractions. Several
groups have published guidelines in an attempt to pro-
vide uniformity of interpretation [13–16]. Consistent
with these guidelines and with the review team’s clinical
practice, this protocol generally refers to “non-reassuring
fetal status or abnormal /CTG/patterns”, rather than the
term “fetal distress”, which is sometimes used inappro-
priately to refer to CTGs that do not meet normal/
reassuring status [17]. Reassuring patterns require no
specific action. Non-reassuring patterns are identified in
approximately 15 % of those with CTG monitoring [18]
and may prompt clinical actions ranging from simple ma-
noeuvres, such as maternal position change, improved
maternal hydration, through to expedited birth of the baby
by caesarean section, forceps or vacuum. These actions
aim to prevent or minimise hypoxia in the fetus.
Compensation mechanisms for decreased oxygen supply:
can the intrapartum CTG identify the baby’s response?
Non-reassuring CTG patterns may reflect adaptations
made by the individual fetus to decreases in oxygen sup-
ply. Inadequate oxygen supply results in anaerobic metab-
olism of glucose, which leads to metabolic acidosis and
the production of lactate. Low pH is a combined measure
of both metabolic acidosis (including base deficit) and the
more labile component, respiratory acidosis.
The differences in individual fetal responses to a de-
crease in oxygen (and therefore differences in fetal heart
rate changes) mean that the positive predictive value of
non-reassuring CTG for adverse outcome is low, al-
though the negative predictive value of a reassuring
pattern is high [18]. This means that a normal CTG
almost always indicates reassuring fetal status, while a
non-reassuring CTG on its own significantly overesti-
mates the occurrence of babies that would have a poor
perinatal outcome if birth were delayed. These features,
combined with marked inter-observer variation in CTG
interpretation by midwives and doctors, result in high
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caesarean section rates for non-reassuring fetal status in
many hospitals [19, 20].
Fetal scalp blood sampling
Collection of a small capillary blood sample from the fetal
scalp (a fetal blood sample) for blood gas analysis has been
used in clinical practice since the 1960s to assist in intra-
partum fetal welfare evaluation [21]. Following identifica-
tion of one abnormal or two non-reassuring features on
the CTG, the National Institute for Health and Care
Excellence in the United Kingdom recommends fetal
blood sampling (FBS) for pH or lactate estimation, with a
published action algorithm based on the result [14]. Fol-
lowing rupture of the amniotic membranes and at cervical
dilatation greater than or equal to approximately 3 cm, an
amnioscope is placed vaginally to allow adequate visu-
alisation of the fetal head. A small sample of blood is
then taken from the fetal scalp. This procedure may be
uncomfortable and intrusive for the mother and is inva-
sive to the baby. Rare complications include fetal scalp
infection and haemorrhage [22, 23] and it is contra-
indicated when the mother is known to have HIV or
viral hepatitis, or where there is suspicion of a bleeding
tendency in the fetus [23, 24].
Traditionally, such testing has required approximately
30 to 50 microlitres of blood, which is often difficult to
obtain [25]. Even when the clinician is able to collect
this quantity of blood, samples are frequently rejected by
the testing equipment due to contamination with air or
amniotic fluid. Some equipment can analyse for other
components, such as lactate. Fetal lactate testing equip-
ment requiring a much smaller blood volume (as little as
5 microlitres) is now available [26].
Fetal blood sampling for pH estimation: what is the
supporting evidence for use?
The Cochrane systematic review of intrapartum CTG
for fetal welfare [27] reported that:
 In a meta-analysis of five RCTs enrolling 18,700
mother/baby pairs, the relative risk (RR) for caesarean
section was 1.96 (95 % confidence intervals [CI] 1.23
to 3.09) for the continuous CTG group compared
with intermittent auscultation of the fetal heart.
 Meta-analysis of six RCTs (n = 15,000) resulted in an
RR of 1.5 (95 % CI 1.10 to 2.06) for caesarean
section when fetal well-being was monitored by
CTG and fetal scalp blood pH sampling, versus
intermittent auscultation.
 Only one of the published RCTs compared
outcomes following allocation to CTG + FBS (pH)
or CTG alone: four of 229 women in the CTG +
FBS group underwent caesarean section, compared
with 41 of 230 in the CTG-only group, yielding a
relative risk of 0.64 (95 % confidence intervals 0.40
to 1.00) [28]. There were no differences in any
immediate infant outcomes (Apgar scores, cord
blood gases, neonatal death, neonatal morbidity,
nursery course).
These trials and the systematic review influenced ob-
stetric opinion toward recommending FBS when a non-
reassuring CTG is identified during labour, for example,
the National Institute for Health and Care Excellence in
the United Kingdom [14] clinical practice guidelines,
which are closely aligned with Australian clinical prac-
tice. Not all countries follow this line of persuasion,
however, with FBS for pH estimation being uncommon
in the United States of America, for example [29].
The use of pH estimation in Australia has declined,
largely replaced by the availability of hand-held bedside
lactate testing units, which require much smaller blood
samples than for pH.
Fetal blood sampling for lactate measurement: an
alternative to pH estimation
A fetal scalp blood sample for lactate measurement
(FBSLM) taken within 60 min prior to birth correlates
well with umbilical arterial and venous lactate, pH and
base excess measured following birth [30]. Umbilical ar-
terial (UA) lactate values correlate well with UA pH and
base deficit values [30, 31].
Allen et al. [32] reported that fetal scalp lactate values
greater than or equal to 4.2 mmol/L offered the best
sensitivity and specificity for detecting clinically import-
ant outcomes. Kruger et al. [25] retrospectively exam-
ined the predictive values of 326 simultaneous fetal scalp
blood estimations of lactate and pH for Apgar scores,
umbilical arterial pH, umbilical arterial base deficit and
neonatal encephalopathy. Cut-off values were the 75th
centile for lactate (4.8 mmol/L) and the 25th centile for
pH (7.20). The area under the receiver operating charac-
teristic (ROC) curve was significantly greater for lactate
than for pH in predicting neonatal encephalopathy and
low Apgar score [25]. These findings and evidence from
animal studies of the effects of lactate on brain tissue
[33, 34] suggest that lactate estimation may be a better
predictor of severe neonatal morbidity than pH.
Lactate values that prompt clinical intervention
Because different lactate values can be simultaneously
recorded from different lactate measurement systems
[35–37], the cut-off lactate value selected to prompt
clinical action must be considered specifically for the
lactate meter in use [2, 37]. The available data support a
lactate value greater than 4.8 mmol/L as a cut-off value
for intervention when measured with the Lactate Pro
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(Arkray, Kyoto, Japan) [38], which is used at the RWH
and included the RWH Clinical Practice Guidelines [39].
Intrapartum lactate values
Observational studies suggest that fetal lactate concen-
trations are constant during the first stage of labour in
the absence of hypoxia, and that intrapartum lactate mea-
surements are better than estimations of pH for the pre-
diction of severe neonatal morbidity [25, 33, 34, 40, 41].
Nordström [42] found that, on average, maternal lactate
rose by 2 mmol/l per 30 min in the second stage of labour.
Fetal lactate concentrations correlate positively with the
duration of active pushing at a rate about half that of the
maternal lactate (1 mmol/L per 30 min) [42]. The ques-
tion of whether this lactate rise is driven by fetal hypoxia
or derived from the mother was investigated by studying
the arterio-venous lactate difference at birth. They found
that the main contributor to the fetal lactate increase is
the fetus itself, especially with prolonged second stage
[42]. This is also supported by animal studies [43]. These
findings suggest that fetal scalp lactate measurements re-
main an appropriate indicator of fetal hypoxia in second
stage, particularly, for example, when the fetal head is rela-
tively high in the mother’s pelvis and a dense epidural an-
algesia is in place that limits the mother’s ability to bear
down and give birth to the baby in a short timeframe (i.e.
minutes). The clinical appropriateness of performing a
FBSLM in response to abnormal fetal heart rate monitor-
ing in active/advanced second stage warrants consider-
ation, where the option of assisting the birth with vacuum
or forceps would be a reasonable option, achievable within
minutes, rather than delaying this intervention to take a
blood sample.
Appraising the evidence for lactate measurement in
labour: Systematic review
There is only one published systematic review of the
clinical effectiveness and risks of fetal scalp lactate sam-
pling used to assess fetal well-being in labour, in the
presence of a non-reassuring CTG [2]. Only two rando-
mised trials [38, 44] compared outcomes following fetal
scalp blood sampling for pH or lactate measurement.
Fetal scalp blood lactate estimation was more likely to
be successfully undertaken than pH, with fewer scalp in-
cisions and results available within 60 s. Larger blood
volumes and longer test times were required for pH
estimation. No randomised trials were identified that
compared the use of CTG-only with CTG and lactate,
although one ongoing trial has been identified (The
SCALP trial [45]) during the process of updating the
published Cochrane systematic review. This creates an
untenable dilemma. Lactate measurement has essentially
replaced pH estimation clinically, but there is no evi-
dence from randomised trials and systematic reviews
supporting its use. The value of using lactate measure-
ments in labour without this evidence is uncertain, given
the contribution that pH estimation has previously been
shown to make for avoiding caesarean birth [46, 47].
The need for a randomised trial of lactate for assessment
of fetal well-being
It is proposed that undertaking this randomised trial is
timely and mandatory because:
 Caesarean section following onset of labour is a
major contributor to the alarmingly high overall
caesarean section rate.
 Caesarean section increases maternal mortality and
morbidity in the index and subsequent pregnancies.
 Caesarean section may increase fetal/neonatal
morbidity in the index pregnancy.
 Fetal blood sampling following identification of a
non-reassuring CTG was previously done for pH
estimation and was considered the best option to
reduce the risk of unnecessary caesarean sections in
many clinical settings.
 Lactate measurement has replaced pH estimation as
the test of choice by FBS in contemporary
Australian clinical practice and also in many
overseas centres.
 Although lactate measurement is possible and the
technology readily available, it is not widely
practiced in Australian and many overseas maternity
centres – that is, a state of equipoise exists.
 There currently exists no RCT data establishing the
benefits and risks of FBSLM in labour.
 There is therefore an urgent need for evidence
about the benefits and risks of lactate measurement
when a non-reassuring CTG has been identified in
labour, to enable childbearing women and their cli-




The primary aim of this randomised trial is to determine
whether the addition of FBSLM during labours compli-
cated by a non-reassuring fetal heart rate cardiotocogra-
phy trace reduces the risk of birth by caesarean section,
compared with monitoring by CTG alone.
Hypothesis
When a woman in labour has a non-reassuring CTG,
she has a 38 % chance of delivery by caesarean section
[12]. We hypothesise that the addition of FSBLM will
reduce this rate from 38 % to 25 %, which is a 35 % rela-
tive reduction.
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Study design
This randomised controlled trial conforms to Consort
Statement standards [48] and is informed by the investi-
gator team’s experience in the evaluation of technology
for fetal welfare assessment [49–52]. The nature of the
RCT necessitates non-blinding of clinicians and partici-
pants. The trial has been registered with the Australian
and New Zealand Clinical Trials Register (registration
number ACTRN12611000172909), and has been approved
by the Human Research Ethics Committee of the Royal
Women’s Hospital, Victoria, Australia – the single site in
which the trial is to be conducted (Project 11/56).
Inclusion criteria
 Abnormal fetal heart rate trace in labour not
improved with conservative measures (maternal
position change, correction of maternal hypotension,
decrease or cessation of oxytocin infusion) (Table 1)
 Ability to give informed consent in English
 Singleton pregnancy
 Gestation ≥ 37 weeks
 Cephalic presentation
 Cervical dilatation ≥ 3 cm
 Ruptured amniotic membranes
Exclusion criteria
 Planned caesarean section
 Known viral infections where FBS is contraindicated
(e.g. hepatitis, HIV)
 Situations requiring immediate delivery, e.g.
significant intrapartum haemorrhage, cord prolapse,
etc.
 Known significant fetal anomaly or bleeding disorder
Trial entry
To maximise participation, women will be recruited to
this trial by way of both a conventional ‘opt-in’ approach,
and a novel ‘opt-out’ strategy implemented following
release in March 2014 of the revised National Health and
Medical Research Council’s statement on ethical conduct
in human research [53], which provided a framework for
the use of opt-out consent.
Opt-in consent
Using verbal and written approaches, women planning
vaginal birth will be informed of the trial during their
antenatal visits, focusing specifically on third trimester
hospital clinic visits. If an abnormal FHR traces emerges
during labour and the woman is able to comprehend the
study, she will be approached to participate.
Opt-out consent
From August 2014, eligible women booked and receiving
antenatal care at the Royal Women’s Hospital will be
provided with written information about the trial at vari-
ous gestations, including the fact that both using and
not using lactate measurement are both common strat-
egies at RWH and are accepted as appropriate by senior
clinical staff. The women will be advised that, if they
subsequently meet the inclusion criteria and none of the
exclusion criteria during labour, they will be part of the
trial unless they let the clinical or research staff know
that they wish to opt-out. They can let the staff know in
a number of ways: verbally, by telephone or email. This
information is then recorded in the woman’s medical
record and in a register, maintained by and accessible to
the appropriate clinicians and researchers. Both opt-in
and opt-out consenting processes will continue from
August 2014.
Randomisation and group allocation
A researcher not otherwise involved with the trial will
use computerised sequence generation with permuted
block randomisation, stratified for parity (nulliparous,
parous), to develop the randomisation sequence that will
be applied through sequentially numbered, sealed,
opaque envelopes. Those women whose CTGs meet the
inclusion criteria will be randomised in a 1:1 ratio to the
CTG-only group or the CTG + lactate group. Clinical
care during labour and birth will continue with the
woman’s obstetric and midwifery team. Neonatal care
will be the provided by the neonatal team, according to
national resuscitation guidelines.
Both groups
The hospital’s clinical practice guideline for CTG man-
agement will be followed for measures to alleviate um-
bilical cord compression and/or improve placental blood
flow to the fetus, such as maternal position change, cor-
rection of hypotension or discontinuation of an oxytocin
infusion. Umbilical venous and arterial cord blood will
be collected at birth for blood gas analysis.
Table 1 Abnormal CTG trace eligible for further evaluation by
fetal scalp blood sampling
Consistent with hospital, national and international guidelines [14, 16, 39]
an abnormal CTG trace eligible for further evaluation by FBS is defined as:
One or more of ● Baseline FHR <100 beats per minute (bpm)
or >170 bpm
● Variability absent or <3 bpm
● Prolonged deceleration (>90s and <5 min)
● Late decelerations
● Complicated variable decelerations
Both of ● Baseline FHR between 100-109 or 161-170
● Baseline FHR variability 3-5 bpm for > 40 mins
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CTG-only group
Following identification of an eligible CTG (Table 1) and
randomisation to the CTG-only arm, monitoring of fetal
well-being will continue. No FBS will be taken, even
when a non-reassuring CTG persists despite measures
for improving the CTG. Timing of and progress to
normal birth, operative vaginal birth or caesarean sec-
tion, including for the indication of non-reassuring fetal
status, will be at the discretion of the clinicians in con-
sultation with the labouring woman.
CTG + lactate group
Following identification of an eligible CTG (Table 1) and
randomisation to the CTG + lactate arm, if a non-
reassuring CTG persists despite measures for improving
the CTG, the timing and options for delivery will in-
corporate a further evaluation of fetal well-being. Fetal
blood sampling for lactate measurement will be under-
taken, with resulting actions as per Table 2 (developed
from the available evidence and aligned with the Clinical
Practice Guideline of the RWH [39]).
Data collection
Baseline demographic and characteristic data will be
abstracted from the participants’ hospital records by the
clinical research midwives. In keeping with the require-
ments of the Consort Statement [48], the Clinical Re-
search Midwives will record the number of women
potentially eligible for enrolment in the RCT, the reasons
for non-enrolment (e.g. laboured too quickly) and lim-
ited data on non-enrolled women that are routinely
collected for clinical audit, for example, mode of birth,
parity, Apgar scores, to achieve representative enrol-
ment. The primary and clinical secondary outcomes will
be abstracted from the participants’ medical records by
the Clinical Research Midwives.
Women’s experiences
We developed a questionnaire of women’s experiences
with labour, monitoring and research specifically for our
fetal oximetry trial, drawing on key concepts from experts
and peer-reviewed literature [51]. The Cronbach’s alpha
(0.83 in each of the study groups) and item-total correl-
ation (p < 0.001) supported the reliability and validity of
the questionnaire. We will use the nine questions of the
ten in the original survey [51] that are relevant to this
lactate trial. These questions will seek a rating of
“poor”, “fair”, “good” or “excellent” in regard to three
domains:
(i) labour
(ii) monitoring of fetal well-being during labour and
(iii)participation in the research.
Provision will also be made for free-text comments.
The questionnaire will be administered by the research
midwives. It will be returned via the internal hospital
mail if completed prior to discharge. If the woman has
been discharged without being given a questionnaire, we
will contact her by phone or mail to send a question-
naire and postage paid envelope for its return. We will
follow women up with one phone call or letter if the
questionnaire is not returned.
Economic analysis
An economic analysis will be undertaken using cost-
effectiveness analysis (CEA) to compare the cost and
effectiveness of the experimental clinical strategy: adding
lactate estimation to conventional CTG monitoring, ver-
sus conventional CTG alone. This method determines
the “price” of the additional outcome purchased by
changing from one practice (CTG-only) to the alterna-
tive strategy (CTG + lactate). The CEA will examine
change in resource use for the primary endpoint: caesar-
ean section. Costs for treatment related expenses will
include direct medical costs, such as fetal monitoring
procedures, equipment, mode of birth and postnatal
stay. Given the uniformity of the treatment environment
in which the study will be undertaken, we consider a
limited perspective of costs from the viewpoint of the
health service, in which we already have experience, will
be appropriate for this evaluation [52, 54, 55].
Study endpoints
Primary study endpoint: caesarean section
The Cochrane systematic review of lactate measurement
in labour identified the caesarean section rate as a key
endpoint for the evaluation of this form of fetal welfare
assessment [2].
Secondary study endpoints
1) Maternal endpoints, identified in the Cochrane
systematic review [2]:
a) Total operative birth (forceps + vacuum +
caesarean section)
b) Total operative vaginal birth (forceps + vacuum)
c) Normal vaginal birth
Table 2 Clinical management for lactate results in the CTG +
lactate group
Lactate (mmol/L) Action
<4.0 mmol/L Repeat FBS in 1 hour if the FHR
abnormality persists
4.0-4.8 mmol/L Repeat FBS within 30 minutes or consider
expediting the birth if rapid rise since
last sample
>4.8 mmol/L Urgent delivery indicated
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d) Caesarean section specifically for the indication of
non-reassuring fetal status
e) Assisted vaginal birth (forceps or vacuum) for
non-reassuring fetal status
f ) Maternal satisfaction with fetal monitoring in
labour
g) Maternal length of hospital stay
2) Fetal/neonatal endpoints
The fetal oximetry trial [50] demonstrated
equivalence in fetal and neonatal outcomes when
comparing the use of CTG with fetal oximetry
added to CTG. This is relevant, because although
poor outcomes resulting from hypoxia are rare,
they are important. For this reason, our team of
investigators includes experienced neonatologists.
Based on recommendations for definitions of
serious outcomes by the Australian New Zealand
Neonatal Network and expert recommendation
for important measures of morbidity at and
beyond term [56, 57], we will record:
a) Composite fetal/neonatal endpoint: Death or
serious outcome for the infant: includes one or
more of fetal death after trial entry; death of a
liveborn infant prior to hospital discharge;
neonatal encephalopathy (stages II/III) [58];
Apgar score <4 at 5 min; care in neonatal
intensive care unit >96 h.
b) Other neonatal morbidity outcomes will
include: individual components of the
composite fetal/neonatal outcome; neonatal
encephalopathy (stages I, II, III) [58]; Apgar
score <7 at 5 min; umbilical cord arterial and
venous and first neonatal blood gas (within
two hours of birth) pH, base deficit and
lactate; resuscitation by bag and mask
ventilation, intubation, external cardiac
massage and/or adrenaline; admission to
neonatal intensive care; neonatal length of
hospital stay.
3) Economic: Cost-effectiveness of fetal
monitoring
4) Considerations related to fetal scalp blood
lactate measurement only: We will also record
the success rate of fetal scalp blood sampling
for fetal lactate and fetal scalp laceration or
infection requiring treatment.
Sample size calculations
Data from the systematic review of CTG + FBS trials and
observational data from Australian hospitals support a
conservative estimate of up to a 40 % relative risk reduc-
tion in caesarean sections when FBS is added to CTG
monitoring [12, 27, 28]. Based on a conservative 35 %
relative reduction in Caesarean Section, from 38 % of
women who exhibit a non-reassuring CTG during
labour to 25 %, a sample size rounded up to 300 in each
group is required (total 600, alpha 0.049 (to allow for
one interim analysis), power 90 %). The trial would also
have 92 % power to detect a 25 % reduction in combined
operative births (caesarean + vacuum + forceps) from
55 % to 41 % [12].
Compliance
Compliance with the protocol for the trial study groups
will be audited by hospital record review of actual at-
tempts to take FBS for lactate estimation in each group.
Barriers to compliance will be identified and, where pos-
sible, addressed as soon as practical during the trial.
Feasibility
The Royal Women’s Hospital is the largest tertiary mater-
nity centre in Victoria, Australia, with over 7000 births an-
nually. The investigator team includes the Head of the
University Department of Obstetrics and Gynaecology,
Neonatologists, maternity team leaders, the Medical and
Midwifery Directors of Birth Suite and clinical researchers
experienced in the evaluation of techniques for fetal
welfare assessment. Several members of the investigator
team co-authored the hospital’s Clinical Practice Guide-
lines for fetal scalp blood sampling in labour.
Two of the investigators (CEE and SPB) have previ-
ously conducted an RCT of intrapartum fetal oximetry,
which was (i) a novel technology that required consider-
able clinician expertise; and (ii) was not standard care.
These factors were noted as barriers to recruitment, as
was the challenge of timing of approach when women
were in labour. Despite these barriers, we successfully
recruited the full sample of 600 in 3.5 years.
Analysis
The consultant statistician for the interim analysis will
present data to the data monitoring committee in un-
labelled study groups. The data management team will
remain blinded to group allocation until the final
analysis. Analysis will be by intention to treat and all
randomised subjects will be included. Demographic in-
formation will be summarised for the groups using de-
scriptive statistics, to ensure the groups are comparable.
Proportions will be compared by Chi-squared analysis,
risk ratios and their 95 % confidence intervals. Continu-
ous variables will be compared by t-tests or their non-
parametric equivalent. Logistic regression will compare
the between-group difference in caesarean section. Time
to event data will be analysed by Kaplan-Meier statistics.
Women’s scores from the maternal perceptions ques-
tionnaire will be compared for the two groups using
Wilcoxon signed rank test.
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Independent data monitoring and safety committee
(DSMC)
The DMSC (to be convened) will include as a mini-
mum an experienced researcher, a statistician and other
personnel with extensive research experience. The
Committee will conduct the interim analysis when 50 %
of the sample has been recruited and their outcomes
are known. A recommendation to stop or modify the
trial will be made to the Steering Committee if: (i) it is
beyond reasonable doubt that the probability of finding
a difference in caesarean section rates between groups
is <0.001; or (ii) serious adverse events are worse in one
group than another.
Personnel
We are an experienced team with a strong track record
in fetal welfare assessment, including the only NHMRC-
funded Australian multicentre randomised trial of fetal
oximetry, with its related Cochrane systematic review
[49–52, 59]. Our team includes authors of the Cochrane
systematic review of intrapartum lactate, co-authors of
the RWH Clinical Practice Guideline for fetal blood
sampling, the Medical and Midwifery Directors of Birth
Suite, obstetric care team leaders, an Epidemiologist,
and Neonatologists with experience in large, inter-
national randomised trials.
The Steering Committee will be chaired by CEE and
will comprise the experienced team of named investiga-
tors, with relevant experience in midwifery, obstetrics,
neonatology, and RCTs. The Data Management Team
will comprise the Chief Investigators and Associate In-
vestigators and the Clinical Research Midwives. Clinical
Research Midwives will conduct the trial on a day-to-
day basis, during office hours. A statistician will be
contracted to assist in setting up and maintaining the
database, providing data to the data monitoring and
safety committee and the interim and final analyses. We
will contract a Health Economist to conduct the eco-
nomic analysis of the trial.
Discussion
This randomised trial will be a world-first. Fetal scalp
blood sampling for lactate measurement following iden-
tification of a non-reassuring CTG in labour has the
potential to reduce caesarean section rates, without
compromising fetal or neonatal well-being. Such a result
would mean that the addition of FBSLM can substan-
tially reduce the health and financial burden from birth
by caesarean section. This outcome has significant
worldwide implications for women’s health during and
following childbirth. Avoiding a caesarean section in an
index pregnancy will influence the health of the mother
in future pregnancies and will influence health service
provision.
Notwithstanding the cost of this trial, there are sub-
stantial economic savings to be realised should the
hypothesis of reducing caesarean section rates be sup-
ported by the trial result [60]. Australian public mater-
nity hospitals receive about $5,000 from the government
for each caesarean section, i.e. twice the amount allo-
cated for a vaginal birth [61]. Even if the results of this
trial support the hypothesis and were then translated
into practice only partially by Australian maternity cen-
tres, the cost of the trial would be covered many times
over within a relatively short time period of several
years. Worldwide, the cost savings would be of great
magnitude.
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